Cipla Targets U.S. With Glaxo’s Advair, Anti-AIDS Drugs

Cipla Ltd. shot to prominence a decade ago by selling AIDS drugs for $1 a day in Africa. Now the Indian generics maker is seeking a bigger slice of the U.S. market with cheaper medicines for asthma and HIV.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.